RoL nr 239 december 2022

Referenser

Leversvikt och läkemedel

1. Michael Andresen. Dosanpassad läkemedelsbehandling vid nedsatt njurfunktion. Rapp Om Läkemedel. 2022 Sep;36–7.

2. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos Biol Fate Chem. 2004 Nov;32(11):1201–8.

3. Andresen Michael. Hur man blir av med ett läkemedel... Rapp Om Läkemedel. 2021 Dec;(233):44–5.

4. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet Lond Engl. 2014 May 17;383(9930):1749–61.

5. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593–608.

6. Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016 Jun;43(12):1330–9.

7. North-Lewis P, editor. Drugs and the liver: a guide to drug handling in liver dysfunction. London: Pharmaceutical Press; 2008. 324 p.

8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 2005 Dec;(60):646–9.

9. Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JPH, Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):45–57.

10. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008 Dec;64(12):1147–61.

11. Salerno F, Badalamenti S. Drug-induced renal failure in cirrhosis. In: Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and . [Internet]. p. 372–82. Available from: https://books.google.se/books?hl=sv&lr=&id=Z3PARx4oYDgC&oi=fnd&pg=PA372&dq=Drug-induced+renal+failure+in+cirrhosis.+Salerno+F,+Badalamenti+S.&ots=hGbWvInkqk&sig=-PGXmYySE3HVZhzQgPi1x8dpS-w&redir_esc=y#v=onepage&q&f=false

12. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and . [Internet]. Available from: https://books.google.se/books?id=Z3PARx4oYDgC&pg=PA357&dq=The+renin-angiotensin-aldosterone+system+in+cirrhosis.&hl=sv&sa=X&ved=2ahUKEwj9-JyKrcL7AhVeQPEDHX_FCnUQ6AF6BAgIEAI#v=onepage&q&f=false

JAK-hämmare, vad är det och hur används de?

1. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci. 2021 Feb 28;22(5):2449.

2. NT-rådet. Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) och Xeljanz (tofacitinib) vid reumatoid artrit Uppföljning av ordnat införande 2021-12-02. [Internet]. NT-rådet; 2021 [cited 2022 Nov 21]. Available from: https://janusinfo.se/download/18.2095f6df17d7ed57a11720d8/1638782355811/Rinvoq-uppfoljning-JAK-hammare-201202.pdf

3. Sanpaolo ER, Rotondo C, Cici D, Corrado A, Cantatore FP. JAK/STAT pathway and molecular mechanism in bone remodeling. Mol Biol Rep. 2020 Nov;47(11):9087–96.

4. Liu E, Aslam N, Nigam G, Limdi JK. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going. Drugs Context. 2022 Apr 8;11:1–17.

5. European Medicines Agency. Inrebic (fedratinib) Sammanfattning av Inrebic och varför det är godkänt inom EU [Internet]. 2020. Available from: https://www.ema.europa.eu/en/documents/overview/inrebic-epar-medicine-overview_sv.pdf

6. FDA. FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older [Internet]. 2022 [cited 2022 Nov 22]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older

7. European Medicines Agency. Cibinqo (abrocitinib) Sammanfattning av Cibinqo och varför det är godkänt inom EU [Internet]. EMA; 2021 [cited 2022 Nov 21]. Available from: https://www.ema.europa.eu/en/documents/overview/cibinqo-epar-medicine-overview_sv.pdf

8. Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022 Mar 4;20(3):425–34.

9. Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021 Nov;40(11):4457–71.

10. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316–26.

11. Jerremalm Elin. Risk för blodpropp i lunga och dödsfall vid för hög dos av tofacitinib [Internet]. www.janusinfo.se. 2019 [cited 2022 Nov 21]. Available from: https:///nyheter/nyheter/2019/riskforblodproppilungaochdodsfallvidforhogdosavtofacitinib.5.558889c7169bd7723e6412a.html

12. Läkemedelsverket. Ytterligare säkerhetsåtgärder för Xeljanz efter granskning [Internet]. https://www.lakemedelsverket.se/. 2021 [cited 2022 Nov 21]. Available from: https://www.lakemedelsverket.se/sv/nyheter/ytterligare-sakerhetsatgarder-for-xeljanz-efter-granskning

13. EMA press office. EMA starts safety review of Janus kinase inhibitors for inflammatory disorders [Internet]. https://www.ema.europa.eu/. 2022 [cited 2022 Nov 21]. Available from: https://www.ema.europa.eu/en/news/ema-starts-safety-review-janus-kinase-inhibitors-inflammatory-disorders

14. Läkemedelsverket. Riskminskningsåtgärder för användning av JAK-hämmare för kroniska inflammatoriska sjukdomar [Internet]. www.lakemedelsverket.se. 2022 [cited 2022 Nov 21]. Available from: https://www.lakemedelsverket.se/sv/nyheter/ema-rekommenderar-riskminskningsatgarder-for-anvandning-av-jak-hammare-for-kroniska-inflammatoriska-sjukdomar

15. Fierce Pharma. EMA cracks down on JAK inflammatory disease drugs, limiting AbbVie's Rinvoq and more on safety risks [Internet]. https://www.fiercepharma.com/. 2022. Available from: https://www.fiercepharma.com/marketing/ema-cracks-down-jak-inflammatory-disease-drugs-limiting-abbvies-rinvoq-and-more-safety